Abstract | OBJECTIVE: MATERIALS AND METHODS: The databases of PubMed and CNKI were electronic searched with the free text word of lung cancer/NSCLC and lentinan. The prospective clinical study reporting the clinical efficacy and safety of lentinan injection combined with chemotherapy in the treatment of NSCLC were reviewed and included in this meta-analysis. The combined treatment efficacy and toxicity of lentinan injection combined with chemotherapy were pooled by Stata 11.0 software. RESULTS: Twelve clinical studies of lentinan injection combined with chemotherapy in the treatment of NSCLC with 458 controls and 492 NSCLCs patients were finally included in this meta-analysis. The pooled results indicated that the objective response rate was significant improved in the lentinan injection combined chemotherapy group compared with chemotherapy group only (relative risk [RR] = 1.31, 95% confidence interval [CI]: 1.14-1.52). The chemotherapy-related toxicity of III/IV gastrointestinal reaction (RR = 0.54, 95% CI: 0.43-0.68) and III/IV granulocytopenia (RR = 0.65, 95% CI: 0.51-0.70) were significant decreased in the combined group. CONCLUSION:
|
Authors | X Yin, J Ying, L Li, H Zhang, H Wang |
Journal | Indian journal of cancer
(Indian J Cancer)
Vol. 52 Suppl 1
Pg. e29-31
(Nov 2015)
ISSN: 1998-4774 [Electronic] India |
PMID | 26548936
(Publication Type: Journal Article, Meta-Analysis, Systematic Review)
|
Chemical References |
- Antineoplastic Agents
- Lentinan
|
Topics |
- Antineoplastic Agents
(therapeutic use)
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Carcinoma, Non-Small-Cell Lung
(drug therapy)
- Humans
- Lentinan
(therapeutic use)
- Lung Neoplasms
(drug therapy)
- Prospective Studies
- Treatment Outcome
|